Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.
Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. · 2014
Read Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. by Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4231726.txt.
Introduction
Ami M. Kabadi, Charles A. Gersbach, and two co-authors packed a multi-tool gene editor into one virus in Nucleic Acids Research in 2014. The CRISPR Cas9 system can cut or switch genes at chosen spots, and its party trick is doing several spots at once. Delivering all the parts evenly into cells, and keeping them on, was the hard part.
Their single lentiviral vector carries the Cas9 enzyme, a reporter gene, and up to four guide RNAs, each under its own promoter, assembled by a quick cloning method. Every guide was expressed well. In both cell lines and primary human cells the vector drove multi-site editing and lasting gene activation at once. The all-in-one design promises steadier experiments in multiplex genome engineering.
Catalog record
| CREATOR | Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector By Ami M Kabadi, David G Ousterout, Isaac B Hilton, Charles A Gersbach Published in: Nucleic Acids Research DOI: 10.1093/nar/gku749 ABSTRACT Abstract Engineered DNA-binding proteins that manipulate the human genome and transcriptome have enabled rapid advances in biomedical research. In particular, the RNA-guided CRISPR/Cas9 system has recently been engineered to create site-specific double-strand breaks for genome editing or to direct targeted transcriptional regulation. A unique capability of the CRISPR/Cas9 system is multiplex genome engineering by delivering a single Cas9 enzyme and two or more single guide RNAs (sgRNAs) targeted to distinct genomic sites. This approach can be used to simultaneously create multiple DNA breaks or to target multiple transcriptional activators to a single promoter for synergistic enhancement of gene induction. To address the need for uniform and sustained delivery of multiplex CRISPR/Cas9-based genome engineering tools, we developed a single lentiviral system to express a Cas9 variant, a reporter gene and up to four sgRNAs from independent RNA polymerase III promoters that are incorporated into the vector by a convenient Golden Gate cloning method. Each sgRNA is efficiently expressed and can mediate multiplex gene editing and sustained transcriptional activation in immortalized and primary human cells. This delivery system will be significant to enabling the potential of CRISPR/Cas9-based multiplex genome engineering in diverse cell types. INTRODUCTION Recent discoveries of novel protein–DNA interactions in various species and systems have led to the development of methods for engineering synthetic proteins that can be targeted to predefined DNA sequences (1–4). These proteins can be fused to diverse effector domains to create new enzymes that modify DNA sequence or transcriptional regulation at any site in the genome. Engineered DNA-binding proteins that manipulate the human genome and transcriptome have enabled important advances in biomedical research, including highly efficient site-specific gene modification (5–12), transcriptional activation (13–20) and epigenetic modification (21–24). Notably, a Phase I clinical study based on ex vivo gene editing using zinc-finger nucleases (ZFNs) recently met defined safety criteria (6,12), demonstrating the clinical applicability of site-specific DNA modification technologies. A significant recent advance in genome engineering is the development of the CRISPR/Cas9 system for nuclease-based genome editing (25–29) and also for transcriptional regulation (15,18,20,22,29–35). In this system, a chimeric single guide RNA (sgRNA) is utilized to direct the Cas9 protein to predefined DNA sequences (36). The sgRNA can be targeted to any desired DNA sequence by exchanging the 20 bp protospacer that confers targeting specificity through complementary base pairing with the desired DNA target. The natural function of Cas9 is to act as a nuclease by creating DNA double-stranded breaks via RuvC and HNH endonuclease domains, each of which cleaves one strand of the target DNA (37). The nuclease domains can be inactivated by two amino acid substitutions (D10A and H840A) to generate a Cas9 protein that has no endonuclease activity but maintains its RNA-guided DNA-binding capacity (36). This deactivated Cas9 (dCas9), in conjunction with the sgRNA, functions as a modular DNA-binding scaffold. We and others have previously shown that this DNA-binding scaffold can be used to mediate gene regulation by fusion of the VP64 transactivation domain or KRAB repression domain to dCas9 (15,18,20,22,29–35). Unlike other genome engineering systems based on zinc finger proteins and transcription activator-like effectors (1,2,4), novel proteins do not need to be engineered for each CRISPR/Cas9 target sequence. Therefore, this technology greatly expedites the process of molecular targeting to new sites by simply modifying the expressed sgRNA molecule. The CRISPR/Cas9 system can simultaneously target multiple distinct genomic loci by co-expressing a single Cas9 protein with two or more sgRNAs, making this system uniquely suited for multiplex gene editing (25,26) or synergistic activation of target genes (15,18). In most cases, this has been achieved by encoding the Cas9 variant and each sgRNA on independent plasmids that are mixed for co-transfection. However, co-transfection of multiple plasmids leads to variable expression levels in each cell due to differences in copy number. Additionally, gene activation following transfection is transient due to dilution of plasmid DNA over time. Moreover, many cell types are not easily transfected and transient gene expression may not be sufficient for achieving the desired effect. To address these limitations, we have developed a user-friendly platform to express Cas9 or a dCas9 variant, a reporter gene and up to four sgRNAs, each from independent Pol III promoters, from a single lentiviral vector. The final vector is readily generated by Golden Gate assembly. We show that each promoter is capable of efficiently expressing sgRNAs that direct similar levels of Cas9 nuclease activity. Furthermore, lentiviral delivery of a single vector expressing Cas9 and four sgRNAs targeting distinct loci resulted in simultaneous multiplex gene editing of all four loci. Finally, we demonstrate tunable transcriptional activation at two endogenous genes that can be either transient or sustained using lentiviral delivery of dCas9VP64 with or without sgRNAs. Notably, we observed efficient and long-term targeted activation of endogenous genes in primary human cells, highlighting the utility and power of this approach. This system is therefore an attractive and efficient method to facilitate multiplex gene editing and long-term transcriptional activation in human cells. MATERIALS AND METHODS Plasmid constructs The gene encoding human codon optimized Cas9 (hCas9) nuclease was obtained from Addgene (Plasmid #41815) (25), and we reported the expression cassette for the Streptococcus pyogenes sgRNA previously (Addgene Plasmid #47108) (18). Additional promoters for mU6 (38), H1 (39) and 7SK (40) Pol III promoters were synthesized using GeneBlocks (IDT) and cloned in place of the hU6 sgRNA expression cassette. A GeneBlock (IDT) was inserted into the 3′ of the hCas9 coding sequence to fuse a T2A skipping peptide and eGFP gene to monitor Cas9 expression. The coding sequence for hCas9-T2A-GFP was then transferred into the FUGW lentiviral expression vector (Addgene Plasmid #14883) containing the human ubiquitin C (hUbC) promoter to drive expression of hCas9-T2A-GFP, as well as restriction sites to facilitate Golden Gate cloning of sgRNA expression cassettes immediately upstream of the hUbC promoter (Figure 2). All plasmids have been made publicly available through the Addgene non-profit plasmid repository (plasmids #53186–53192). [Figure: Golden Gate assembly of single lentiviral vectors encoding CRISPR/Cas9 and multiple sgRNA expression cassettes. In the first step, individual sgRNAs are cloned into separate expression vectors and sequence verified. Fragments containing each sgRNA expression cassette are then transferred into a Cas9-expressing lentivirus in step 2 by Golden Gate assembly as shown. Black triangles shown in the lentiviral plasmid represent loxP sites flanking the entire sgRNA and Cas9 expression cassette.] Protocol for assembly of custom lentiviral vectors Assembly of custom lentiviral vectors expressing up to four sgRNAs of choice and active Cas9, dCas9 or dCas9VP64 can be accomplished in <5 days. The cloning method makes use of Golden Gate cloning and type IIS restriction enzymes that cleave outside their recognition sequence to create unique overhangs. Golden Gate assembly expedites cloning as all four expression cassettes are ligated into the final lentiviral vector in one step. The lentiviral vector expresses either active Cas9, dCas9 or dCas9VP64 in addition to one, two, three or four sgRNAs expressed from independent promoters. - Step 1: Anneal single stranded oligos containing each 20 bp protospacer to create overhangs for ligation into the desired donor promoter vector. Two